In Brief: Forest Labs' Infasurf
Forest Labs' Infasurf: NDA filed March 13 for calf lung surfactant for prevention and treatment of respiratory distress syndrome in premature infants. The product would compete in the RDS market with Abbott's Survanta, also a calf lung product, and Burroughs Wellcome's Exosurf, which is synthetic. The NDA is based on Phase III trials in approximately 1,000 infants. The product has been available in the U.S. under a Treatment IND and has been used to treat more than 10,000 infants. Forest has been touting Infasurf as a superior product based on its effects, which last longer, and the fact that fewer doses are needed compared to other lung surfactants...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth